EXG-34217

EXG-34217 is an autologous cell and gene therapy developed by Elixirgen Therapeutics for the treatment of telomere biology disorders (TBDs), including bone marrow failure syndromes such as dyskeratosis congenita and Fanconi anemia. The therapy consists of a single dose of the patient’s own CD34+ hematopoietic stem cells that are transiently modified ex vivo to express Zinc finger and SCAN domain containing protein 4 (ZSCAN4), a protein that regulates telomere elongation and genome stability independently of telomerase. By expressing ZSCAN4, the treated cells achieve telomere extension, which addresses the underlying cause of TBDs—abnormally short telomeres leading to premature cellular aging and bone marrow failure. Early clinical results have shown successful ex vivo telomere lengthening in patients’ CD34+ cells, improvement in blood counts, and no significant adverse events. The drug has received Orphan Drug designation, Rare Pediatric Disease designation, and Regenerative Medicine Advanced Therapy (RMAT) status from the FDA[1][2][5][6].